替诺福韦与恩替卡韦对慢性HBV感染者肝细胞癌风险影响的系统评价与Meta分析
该系统评价与Meta分析纳入15项研究共61,787例慢性HBV感染者,比较替诺福韦酯(TDF)与恩替卡韦对肝细胞癌(HCC)发生率的影响。结果显示TDF治疗与HCC风险显著低于恩替卡韦相关(HR 0.80,95%CI 0.69-0.93,P=.003),死亡或移植风险两组无统计学差异。作者认为需随机试验支持该发现。
要点
- TDF治疗与HCC风险显著低于恩替卡韦相关(HR 0.80,95%CI 0.69-0.93)。
- 死亡或移植风险在TDF与恩替卡韦组间无统计学差异(HR 0.93,95%CI 0.73-1.17)。
- 作者认为需随机试验支持该发现。
核心结论
- 在慢性HBV感染者的Meta分析中,TDF治疗与HCC风险较恩替卡韦显著降低20%相关。
- 作者认为需随机试验支持该发现。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE、EMBASE、Web of Science和Cochrane Library 2010年至2019年的全文文章和会议摘要。
- 最终分析纳入15项研究,共61,787例患者,其中16,101例接受TDF,45,686例接受恩替卡韦。
- 采用随机效应模型分析数据,并通过敏感性分析、Meta回归和亚组分析探讨异质性来源。
主要发现
- TDF治疗与HCC风险显著低于恩替卡韦相关(HR 0.80,95%CI 0.69-0.93,P=.003;I²=13%)。
- 在倾向评分匹配队列和肝硬化亚队列的敏感性和亚队列分析中,TDF较恩替卡韦的HCC风险降低持续存在。
- Meta回归分析中,纳入失代偿期肝硬化患者和样本量是对研究间异质性影响最大的因素。
- 亚组分析显示TDF与恩替卡韦组间死亡或移植发生率无统计学差异(HR 0.93,95%CI 0.73-1.17,P=.519;I²=6%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需随机试验支持该发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Tenofovir disoproxil fumarate (TDF) and entecavir are recommended as first-line treatments for chronic hepatitis B virus (HBV) infection. However, there is debate over the comparative effectiveness of these drugs in preventing hepatocellular carcinoma (HCC). We performed a systematic review and meta-analysis of the effectiveness of TDF vs entecavir in reducing the incidence of HCC among patients with chronic HBV infection. METHODS: We performed a systematic review of the MEDLINE, EMBASE, Web of Science, and Cochrane Library from 2010 through 2019 for full-text articles and conference abstracts on studies of effects of TDF vs entecavir in patients with HBV infection. Extracted data were analyzed with the random-effects model. Potential sources of heterogeneity were investigated using sensitivity, meta-regression, and subgroup analyses. RESULTS: Our final analysis comprised 15 studies (61,787 patients; 16,101 patients given TDF and 45,686 given entecavir). TDF treatment was associated with a significantly lower risk of HCC than entecavir (hazard ratio, 0.80; 95% CI, 0.69-0.93; P = .003; I2 = 13%). The lower risk of HCC in patients given TDF compared with entecavir persisted in sensitivity and subcohort analyses performed with propensity score-matched cohorts and cirrhosis subcohorts. Inclusion of patients with decompensated cirrhosis and the sample size were the factors with the largest effects on between-study heterogeneity in meta-regression analyses. Subsequent subgroup analyses showed no statistical differences in the incidence of death or transplantation (hazard ratio, 0.93; 95% CI, 0.73-1.17; P = .519; I2 = 6%) between patients given TDF vs entecavir. CONCLUSIONS: In a meta-analysis of studies of patients with chronic HBV infection, we found that TDF treatment was associated with a significantly lower (20%) risk of HCC than entecavir treatment. Randomized trials are needed to support this finding.
引用
- Choi WM, Choi J, Lim YS, et al. Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2020. PMID: 32407970. doi:10.1016/j.cgh.2020.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。